Windtree Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Windtree Therapeutics

26/11/2024 22:55

* Windtree Therapeutics Inc  WINT.OQ  reported a quarterly
adjusted loss of $5.54​​ per share for the quarter ended
September 30, lower than the same quarter last year, when the
company reported EPS of -86 cents.  The lone analyst forecast
for the quarter was for a loss of $2.27 per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Windtree Therapeutics Inc's reported EPS for the quarter
was a
loss of $4.23​.
    * The company reported a quarterly loss of $3.75 million.
    * Windtree Therapeutics Inc shares had fallen by 76.7% this
quarter and lost 95.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Windtree
Therapeutics Inc is $7.00 
This summary was machine generated from LSEG data November 26 at
10:54 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -2.27          -5.54          Missed
 Jun. 30 2024      -8.11          -20.91         Missed
 Dec. 31 2023      -0.94          -0.74          Beat